How well does Gilteritinib(Xospata) work?

A summary of the drug's clinical performance.

Clinical Efficacy in Studies

The efficacy of XOSPATA was established based on the rate of complete remission (CR) or complete remission with partial hematologic recovery (CRh). In the ADMIRAL trial, the CR/CRh rate was 21% at the interim analysis. The median overall survival for patients treated with XOSPATA was 9.3 months compared to 5.6 months for those receiving chemotherapy, demonstrating a significant survival benefit.